Further uncertainty for biotech/agritech patent applicants
Are products exclusively obtained by essentially biological processes patentable at the EPO?
Read moreAre products exclusively obtained by essentially biological processes patentable at the EPO?
Read moreRichard Bray and Samuel Bird discuss the patentability of mobile apps.
Read moreEli Lilly v Genentech: the question of SPCs based on third party MAs is referred to the CJEU.
Read moreLikely to affect the patentability of ‘simulation’ methods, Howard Read explores the issues behind a European Patent Office (EPO) referral to the Enlarged Board of Appeal (EBA).
Read moreAfter years of controversy, the Technical Board of Appeal (TBA) of the EPO has recently decided that products obtained by essentially biological processes can be patent protected (T1063/18).
Read moreWhat’s the problem with ‘functional limitations’?
Read more